Genentech/NNP Inc./NNP said/VBD 0/-NONE- third-quarter/JJ profit/NN more/RBR than/IN doubled/VBD to/TO $/$ 11.4/CD million/CD *U*/-NONE- ,/, or/CC 13/CD cents/NNS a/DT share/NN ,/, from/IN a/DT depressed/JJ 1988/CD third-quarter/JJ performance/NN of/IN $/$ 5.3/CD million/CD *U*/-NONE- ,/, or/CC six/CD cents/NNS a/DT share/NN ./.
Revenue/NN rose/VBD 23/CD %/NN to/TO $/$ 100/CD million/CD *U*/-NONE- from/IN $/$ 81.6/CD million/CD *U*/-NONE- ./.
Net/JJ product/NN sales/NNS accounted/VBD for/IN $/$ 76/CD million/CD *U*/-NONE- ,/, up/RB from/IN $/$ 57.5/CD million/CD *U*/-NONE- a/DT year/NN earlier/RB ./.
Sales/NNS of/IN the/DT heart/NN drug/NN TPA/NNP were/VBD $/$ 43.6/CD million/CD *U*/-NONE- ,/, better/JJR than/IN last/JJ year/NN 's/POS depressed/JJ third/JJ period/NN when/WRB the/DT company/NN sold/VBD just/RB $/$ 29.1/CD million/CD *U*/-NONE- of/IN the/DT drug/NN *T*-1/-NONE- ./.
But/CC TPA/NNP sales/NNS fell/VBD below/IN levels/NNS for/IN this/DT year/NN 's/POS first/JJ and/CC second/JJ quarter/NN sales/NNS of/IN $/$ 48/CD million/CD *U*/-NONE- ,/, */-NONE- cooling/VBG investors/NNS ./.
Genentech/NNP stock/NN fell/VBD 12.5/CD cents/NNS in/IN trading/NN yesterday/NN on/IN the/DT New/NNP York/NNP Stock/NNP Exchange/NNP to/TO $/$ 20.125/CD *U*/-NONE- ./.
In/IN the/DT nine/CD months/NNS ,/, net/JJ income/NN slid/VBD 21/CD %/NN to/TO $/$ 28.4/CD million/CD *U*/-NONE- ,/, or/CC 33/CD cents/NNS a/DT share/NN ,/, from/IN $/$ 36/CD million/CD *U*/-NONE- ,/, or/CC 42/CD cents/NNS a/DT share/NN ./.
Revenues/NNS climbed/VBD 18/CD %/NN to/TO $/$ 289/CD million/CD *U*/-NONE- from/IN $/$ 245.3/CD million/CD *U*/-NONE- ./.
``/`` We/PRP continue/VBP *-1/-NONE- to/TO be/VB on/IN target/NN for/IN .../: */-NONE- increasing/VBG TPA/NNP sales/NNS 20/CD %/NN to/TO 25/CD %/NN this/DT year/NN ,/, ''/'' said/VBD *T*-2/-NONE- founder/NN and/CC Chief/NNP Executive/NNP Officer/NNP Robert/NNP Swanson/NNP ./.
But/CC some/DT analysts/NNS remain/VBP sour/JJ on/IN the/DT company/NN ./.
``/`` TPA/NNP sales/NNS are/VBP down/RB quarter/NN to/TO quarter/NN ./.
Expenses/NNS are/VBP flat/JJ and/CC that/DT 's/VBZ a/DT good/JJ sign/NN ./.
There/EX 's/VBZ contract/NN revenue/NN from/IN -LCB-/-LRB- limited/JJ research/NN and/CC development/NN -RCB-/-RRB- partnerships/NNS ./.
But/CC I/PRP still/RB think/VBP 0/-NONE- the/DT fundamentals/NNS are/VBP poor/JJ ,/, ''/'' said/VBD *T*-1/-NONE- Denise/NNP Gilbert/NNP ,/, an/DT analyst/NN with/IN Montgomery/NNP Securities/NNPS in/IN San/NNP Francisco/NNP ./.
Genentech/NNP faces/VBZ competition/NN in/IN the/DT cardiac-drug/JJ market/NN from/IN SmithKline/NNP Beecham/NNP PLC/NNP 's/POS heart/NN drug/NN Eminase/NNP ,/, expected/VBN */-NONE- to/TO receive/VB market/NN approval/NN shortly/RB ./.
And/CC Genentech/NNP is/VBZ n't/RB likely/JJ *-1/-NONE- to/TO have/VB any/DT new/JJ products/NNS ready/JJ for/IN market/NN until/IN at/IN least/JJS 1992/CD ,/, Ms./NNP Gilbert/NNP added/VBD 0/-NONE- *T*-2/-NONE- ./.
``/`` The/DT company/NN 's/POS stock/NN is/VBZ trading/VBG at/IN 40/CD times/NNS next/JJ year/NN 's/POS numbers/NNS ,/, and/CC that/DT 's/VBZ too/RB much/JJ ,/, ''/'' she/PRP said/VBD *T*-1/-NONE- ./.
On/IN the/DT plus/JJ side/NN ,/, Genentech/NN is/VBZ benefiting/VBG from/IN a/DT lower/JJR tax/NN rate/NN due/JJ to/TO its/PRP$ research/NN outlays/NNS ,/, giving/VBG a/DT boost/NN to/TO earnings/NNS ,/, she/PRP said/VBD 0/-NONE- *T*-1/-NONE- ./.

